Earlier this month, Biogen (BIIB) stock popped on news of the FDA (U.S. Food and Drug Administration) approving its Alzheimer’s treatment aducanumab (to be marketed as Aduhelm). On the day of the announcement, the biotech giant soared from $286.14 per share, to as much as $468.55 per share, before settling at $395.85 per share. Since its 38.3% one-day pop on June 7, shares have traded sideways, sliding slightly in recent days. (See Biogen Stock Chart on TipRanks) The question now is whether shar
Biogen Controversy could Detract from Stock Gains
2021-06-27T12:06:55-04:00June 27th, 2021|
Related Posts
-
Why Have Stocks Soared Since The April Lows?
May 19th, 2024